{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:21:42Z","timestamp":1791357702625,"version":"4.3.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017459","name":"Allergan Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s10620-024-08297-w","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T11:02:12Z","timestamp":1708772532000},"page":"1626-1635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Healthcare Utilization Patterns: Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Gastroesophageal Reflux Disease"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8647-5933","authenticated-orcid":false,"given":"Natasha","family":"Koloski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0710-1691","authenticated-orcid":false,"given":"Ayesha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-1264","authenticated-orcid":false,"given":"Iain","family":"Kaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-4294","authenticated-orcid":false,"given":"Ronen","family":"Ben Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2537-3092","authenticated-orcid":false,"given":"Nicholas J.","family":"Talley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-4938","authenticated-orcid":false,"given":"Michael P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-2358","authenticated-orcid":false,"given":"Gerald","family":"Holtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"8297_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","volume":"154","author":"JE Richter","year":"2018","unstructured":"Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology 2018;154:267\u2013276.","journal-title":"Gastroenterology"},{"key":"8297_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","volume":"152","author":"GG Kaplan","year":"2017","unstructured":"Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152:313\u201321.e2.","journal-title":"Gastroenterology"},{"key":"8297_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","volume":"160","author":"AD Sperber","year":"2021","unstructured":"Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 2021;160:99-114.e3.","journal-title":"Gastroenterology"},{"key":"8297_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","volume":"7","author":"J Burisch","year":"2013","unstructured":"Burisch J, Jess T, Martinato M et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322\u2013337.","journal-title":"J Crohns Colitis"},{"key":"8297_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/IJGM.S58888","volume":"7","author":"A Gikas","year":"2014","unstructured":"Gikas A, Triantafillidis JK. The role of primary care physicians in early diagnosis and treatment of chronic gastrointestinal diseases. Int J Gen Med 2014;7:159\u2013173.","journal-title":"Int J Gen Med"},{"key":"8297_CR6","doi-asserted-by":"publisher","first-page":"e017775","DOI":"10.1136\/bmjopen-2017-017775","volume":"7","author":"JJG Wammes","year":"2017","unstructured":"Wammes JJG, Tanke M, Jonkers W et al. Characteristics and healthcare utilisation patterns of high-cost beneficiaries in the Netherlands: a cross-sectional claims database study. BMJ Open 2017;7:e017775.","journal-title":"BMJ Open"},{"key":"8297_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756284818818326","volume":"12","author":"B Lacy","year":"2019","unstructured":"Lacy B, Ayyagari R, Guerin A et al. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap Adv Gastroenterol 2019;12:1\u201317.","journal-title":"Therap Adv Gastroenterol"},{"key":"8297_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","volume":"156","author":"AF Peery","year":"2019","unstructured":"Peery AF, Crockett SD, Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019;156:254\u201372.e11.","journal-title":"Gastroenterology"},{"key":"8297_CR9","doi-asserted-by":"crossref","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900\u201320","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"8297_CR10","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s10620-017-4599-6","volume":"62","author":"NA Koloski","year":"2017","unstructured":"Koloski NA, Jones M, Hammer J et al. The validity of a new Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for evaluating symptoms in the clinical setting. Dig Dis Sci 2017;62:1913\u20131922.","journal-title":"Dig Dis Sci"},{"key":"8297_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/apt.12938","volume":"40","author":"C Canavan","year":"2014","unstructured":"Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:1023\u20131034.","journal-title":"Aliment Pharmacol Ther"},{"key":"8297_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","volume":"26","author":"KT Park","year":"2020","unstructured":"Park KT, Ehrlich OG, Allen JI et al. The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis Foundation. Inflamm Bowel Dis 2020;26:1\u201310.","journal-title":"Inflamm Bowel Dis"},{"key":"8297_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-014-0164-8","volume":"32","author":"AJ Gawron","year":"2014","unstructured":"Gawron AJ, French DD, Pandolfino JE et al. Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics 2014;32:745\u2013758.","journal-title":"Pharmacoeconomics"},{"key":"8297_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00520-010-0913-y","volume":"19","author":"H McKenzie","year":"2011","unstructured":"McKenzie H, Hayes L, White K et al. Chemotherapy outpatients\u2019 unplanned presentations to hospital: a retrospective study. Support Care Cancer 2011;19:963\u2013969.","journal-title":"Support Care Cancer"},{"key":"8297_CR15","doi-asserted-by":"crossref","unstructured":"Qin D, Yue L, Xue B, et al. Pharmacological treatments for patients with irritable bowel syndrome. An umbrella review of systematic reviews and meta-analyses. Medicine (Baltimore) 2019;98:e15920.","DOI":"10.1097\/MD.0000000000015920"},{"key":"8297_CR16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1053\/j.gastro.2018.08.021","volume":"155","author":"CJ Black","year":"2018","unstructured":"Black CJ, Burr NE, Quigley EMM et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology 2018;155:1753\u20131763.","journal-title":"Gastroenterology"},{"key":"8297_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jhn.12385","volume":"29","author":"YA McKenzie","year":"2016","unstructured":"McKenzie YA, Bowyer RK, Leach H et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet 2016;29:549\u2013575.","journal-title":"J Hum Nutr Diet"},{"key":"8297_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/apt.15001","volume":"48","author":"AC Ford","year":"2018","unstructured":"Ford AC, Harris LA, Lacy BE et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018;48:1044\u20131060.","journal-title":"Aliment Pharmacol Ther"},{"key":"8297_CR19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.gastro.2018.09.036","volume":"156","author":"N Bray","year":"2019","unstructured":"Bray N, Koloski NA, Jones MP et al. A multidisciplinary integrated treatment approach is superior to standard care for functional gastrointestinal disorders (FGIDs): a case-control study [abstract]. Gastroenterology 2019;156:273.","journal-title":"Gastroenterology"},{"key":"8297_CR20","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.mayocp.2018.04.032","volume":"93","author":"M Camilleri","year":"2018","unstructured":"Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc 2018;93:1858\u20131872.","journal-title":"Mayo Clin Proc"},{"key":"8297_CR21","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1053\/j.gastro.2004.02.020","volume":"126","author":"GF Longstreth","year":"2004","unstructured":"Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004;126:1665\u20131673.","journal-title":"Gastroenterology"},{"key":"8297_CR22","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1111\/j.1572-0241.2001.05258.x","volume":"96","author":"RL Levy","year":"2001","unstructured":"Levy RL, Von Korff M, Whitehead WE et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122\u20133129.","journal-title":"Am J Gastroenterol"},{"key":"8297_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12876-015-0398-8","volume":"15","author":"CE Flik","year":"2015","unstructured":"Flik CE, Laan W, Smout AJPM et al. Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands. BMC Gastroenterol 2015;15:168.","journal-title":"BMC Gastroenterol"},{"key":"8297_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12876-019-0985-1","volume":"19","author":"J Tack","year":"2019","unstructured":"Tack J, Stanghellini V, Mearin F et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol 2019;19:69.","journal-title":"BMC Gastroenterol"},{"key":"8297_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.brat.2016.07.006","volume":"88","author":"GD Gudleski","year":"2017","unstructured":"Gudleski GD, Satchidanand N, Dunlap LJ et al. Predictors of medical and mental health care use in patients with irritable bowel syndrome in the United States. Behav Res Ther 2017;88:65\u201375.","journal-title":"Behav Res Ther"},{"key":"8297_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2050640618821804","volume":"7","author":"K Van den Houte","year":"2019","unstructured":"Van den Houte K, Carbone F, Pannemans J et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United European Gastroenterol J 2019;7:307\u2013315.","journal-title":"United European Gastroenterol J"},{"key":"8297_CR27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41575-020-0270-3","volume":"17","author":"P Moayyedi","year":"2020","unstructured":"Moayyedi P, Simr\u00e9n M, Bercik P. Evidence-based and mechanistic insights into exclusion diets for IBS. Nat Rev Gastroenterol Hepatol 2020;17:406\u2013413.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8297_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1572-0241.2000.01735.x","volume":"95","author":"NA Koloski","year":"2000","unstructured":"Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000;95:67\u201371.","journal-title":"Am J Gastroenterol"},{"key":"8297_CR29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1053\/gast.2000.16484","volume":"119","author":"IM Gralnek","year":"2000","unstructured":"Gralnek IM, Hays RD, Kilbourne A et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654\u2013660.","journal-title":"Gastroenterology"},{"key":"8297_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12955-019-1174-1","volume":"17","author":"\u00c5 Faresj\u00f6","year":"2019","unstructured":"Faresj\u00f6 \u00c5, Walter S, Norlin AK et al. Gastrointestinal symptoms - an illness burden that affects daily work in patients with IBS. Health Qual Life Outcomes 2019;17:113.","journal-title":"Health Qual Life Outcomes"},{"key":"8297_CR31","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.clinthera.2006.10.010","volume":"28","author":"P Par\u00e9","year":"2006","unstructured":"Par\u00e9 P, Gray J, Lam S et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clin Ther 2006;28:1726\u20131735.","journal-title":"Clin Ther"},{"key":"8297_CR32","doi-asserted-by":"crossref","unstructured":"Layer P, Andresen V, Pehl C, et al. [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol 2011;49:237\u201393.","DOI":"10.1055\/s-0029-1245976"},{"key":"8297_CR33","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1136\/gutjnl-2016-311715","volume":"65","author":"KM Fock","year":"2016","unstructured":"Fock KM, Talley N, Goh KL et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett\u2019s oesophagus. Gut 2016;65:1402\u20131415.","journal-title":"Gut"},{"key":"8297_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000219365","volume":"80","author":"IM Modlin","year":"2009","unstructured":"Modlin IM, Hunt RH, Malfertheiner P et al. Diagnosis and management of non-erosive reflux disease \u2013 the Vevey NERD Consensus Group. Digestion 2009;80:74\u201388.","journal-title":"Digestion"},{"key":"8297_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1472-6963-9-17","volume":"9","author":"C Pieper","year":"2009","unstructured":"Pieper C, Haag S, Gesenhues S et al. Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders \u2013 an evaluation study. BMC Health Serv Res 2009;9:17.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"8297_CR36","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1111\/j.1572-0241.2002.05783.x","volume":"97","author":"NA Koloski","year":"2002","unstructured":"Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol Suppl 2002;97(9):2290\u20132299.","journal-title":"Am J Gastroenterol Suppl"},{"key":"8297_CR37","first-page":"220","volume":"89","author":"A Chira","year":"2016","unstructured":"Chira A, Filip M, Dumitra\u015fcu DL. Patterns of alternation in irritable bowel syndrome. Clujul Med 2016;89:220\u2013223.","journal-title":"Clujul Med"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08297-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08297-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08297-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T16:08:43Z","timestamp":1715875723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08297-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["8297"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08297-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"12 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Natasha Koloski, Ayesha Shah, Ronen Ben Jacob, and Michael P. Jones disclose no conflicts. Iain Kaan is a former employee of AbbVie. Nicholas J Talley's disclosures include\u00a0Intrinsic Medicine (2022) (human milk oligosaccharide), Alimentry (2023) (gastric mapping), Agency for Health Care Research and Quality (fiber and laxation) (2024), outside the submitted work. In addition, Dr. Talley has a patent Nepean Dyspepsia Index (NDI) 1998, a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo\/Talley, \u201cDiagnostic marker for functional gastrointestinal disorders\u201d Australian Provisional Patent Application 2021901692, \u201cMethods and compositions for treating age-related neurodegenerative disease associated with dysbiosis\u201d US Patent Application No. 63\/537,725. Financial support: Dr. Talley is supported by funding from the National Health and Medical Research Council (NHMRC) to the Centre for Research Excellence in Digestive Health and he holds an NHMRC Investigator grant and a research grant from Defence. Gerald Holtmann received unrestricted educational support from the Falk Foundation. Research support was provided via the Princess Alexandra Hospital, Brisbane by GI Therapies Pty Ltd, Takeda Development Center Asia, Pty Ltd, Eli Lilly Australia Pty Ltd, F.\u00a0Hoffmann-La Roche Ltd, MedImmune Ltd, Celgene Pty Ltd, Celgene International II Sarl, Gilead Sciences Pty Ltd, Quintiles Pty Ltd, Vital Food Processors Ltd, Datapharm Australia Pty Ltd Commonwealth Laboratories, Pty Ltd, Prometheus Laboratories, FALK GmbH & Co KG, Nestle Pty Ltd, Mylan, and Allergan (prior to acquisition by AbbVie Inc.). Dr. Holtmann is also a patent holder for a biopsy device to take aseptic biopsies (US 20150320407 A1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}